Drug Profile
Oxybutynin transmucosal - Endo
Alternative Names: AA-4010Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Auxilium Pharmaceuticals
- Developer Endo International
- Class Alkynes; Antispasmodics; Carbocyclic acids; Cyclohexanes; Diethylamines; Esters; Mandelic acids; Skin disorder therapies; Small molecules
- Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Overactive bladder
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Overactive bladder in USA (Transmucosal, Film)
- 29 Jan 2015 Auxilium Pharmaceuticals has been acquired by Endo International
- 06 May 2009 Transmucosal oxybutynin is available for licensing (http://www.auxilium.com)